drugset / Trial / NCT07098052

A Study of HDM2020 in Patients With Advanced Solid Tumors

NCT07098052 ↗

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: * Is the drug safe and tolerable ? * Does the drug exhibit antitumor activity ? Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.

Timeline

Start
2025-08-11
Primary completion
2026-09-30
Completion
2027-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HDM2020 Other / unclassified — —

Indications